Pharmaceuticals & Therapeutics

Backed by $180M, Celea Therapeutics is deploying a bold head-to-head superiority trial, aiming to prove its drug isn't just an alternative but a new standard.

The biotech's complex warrant restructuring is more than a balance sheet clean-up; it's a strategic masterstroke paving the way for its MASH drug.

Serina Therapeutics' Parkinson's drug SER-252 advances, but the real story is its POZ Platform, a technology that could reshape drug delivery.

Vera Therapeutics just secured its first drug approval. Now, it's bringing in a regulatory heavyweight. We deconstruct the strategy behind the move.

As Immunic executives meet investors, the real audience is the future. With pivotal data on its MS drug due this year, the firm is navigating a high-risk path.

Foresee Pharmaceuticals signals a major shift to commercialization, appointing Brian J. Groch to lead the launch of its 6-month CPP treatment, FP-001.

With a landmark NEJM publication and FDA approval, Rhythm Pharma's setmelanotide offers hope for a rare obesity, proving a potent strategy for niche markets.

Supplement giant Niagen Bioscience is betting big on a new drug for a rare disease. Can its NAD+ science make the leap from wellness to a real cure?

With a PDUFA date set, Arcutis' ZORYVE could soon offer a once-daily, non-steroidal cream for infants, addressing a massive unmet need for families.

With record Q1 sales and key milestones for iDose® TR and Epioxa, all eyes are on Glaukos's July 29 financial release for its next growth chapter.

Keenova Therapeutics' positive Phase 3 results for XIAFLEX could bring the first-ever approved drug for plantar fibromatosis, a painful, disabling condition.

For families battling Duchenne, treatment is a daily trade-off. Now, a new drug class promises to ease this burden, signaling a new era for rare disease care.

After a clinical hold on its lead drug, Quantum BioPharma is spending heavily on marketing. Is it a bold play for survival or a sign of desperation?

MEDIPOST's Phase III trial for knee osteoarthritis isn't just a medical milestone; it's a test case for a faster regulatory path using global data.

Known for its athletic tape, KT is making a strategic leap into the crowded OTC pain relief aisle. Is this a brilliant brand extension or a risky bet?

Cytokinetics is set to unveil groundbreaking data for aficamten, a therapy that could become the first-ever approved treatment for non-obstructive HCM.

The FDA has fast-tracked mitapivat for sickle cell disease, offering new hope for patients. But a closer look reveals the high stakes of this strategy.

Saol Therapeutics' NDA resubmission isn't just a second chance; it's a calculated maneuver signaling a new playbook for navigating the FDA in rare disease.

As OKYO Pharma woos investors with a promising eye drug, it carries the hopes of patients with debilitating pain. A look at the science, stakes, and systems.

With a major FDA decision pending, Aquestive Therapeutics pitches its game-changing anaphylaxis film, Anaphylm, to Wall Street's top healthcare investors.